Slide 1: 4th Quarter Fiscal 2026 Earnings Presentation
4th Quarter Fiscal 2026 Earnings Presentation August 25, 2026
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use o
Slide 3: SelectQuote Year-in-Review
SelectQuote Year-in-Review Healthcare Services Senior Cash Flow ~$50M 26% $40M+ Annualized Adj. EBITDA Exit Year-over-Year improvement in Adj. EBITDA Margin Run-Rate Operating Cash Flow 3
Slide 4: Technology Advantage Leads to Operating Efficiencies
Technology Advantage Leads to Operating Efficiencies Pharmacy Management • Optimized end-to-end sales funnel System (PMS) maximizing agent efficiency Custom-built system Enrollment that unlocks continued Support operational efficiency • Streamlined corporate functions with Agent Sales gains focus on
Slide 5: 2026 Consolidated Financial Summary
2026 Consolidated Financial Summary Revenue Adjusted EBITDA* $MM $MM $1,618 $1,527 $126 $109 $345 $322 $12 $3 4Q25 4Q26 FY25 FY26 4Q25 4Q26 FY25 FY26 *See "Non-GAAP Financial Measures" section on slide 2 5
Slide 6: Growing Operating Cash Flow
Growing Operating Cash Flow Commentary Operating Cash Flow $MM • $44 million year-over-year improvement in operating cash driven by disciplined $32 execution across every division • Strong Senior operating results despite a dynamic market backdrop • Healthcare Services driving more operating cash pe
Slide 7: Senior Financial Summary
Senior Financial Summary Revenue Adjusted EBITDA $MM $MM $162 $600 $576 $148 $82 $8 $8 $73 4Q25 4Q26 FY25 FY26 4Q25 4Q26 FY25 FY26 7
Slide 8: Healthcare Services KPIs
Healthcare Services KPIs Revenue & Adjusted EBITDA SELECTRX Members $MM 117 113 108 107 109 $214 $221 $231 $199 $194 4Q25 1Q26 2Q26 3Q26 4Q26 PBM partner reimbursement negotiation impact $12 $12 $7 $5 $1 4Q25 1Q26 2Q26 3Q26 4Q26 REVENUE ADJUSTED EBITDA 8
Slide 9: Life Financial Summary
Life Financial Summary Revenue Adjusted EBITDA $MM $MM $186 $173 $27 $27 $48 $48 $10 $7 4Q25 4Q26 FY25 FY26 4Q25 4Q26 FY25 FY26 9
Slide 10: FY27 Guidance - Driving Significant Cash Flow Improvement
FY27 Guidance - Driving Significant Cash Flow Improvement Revenue $1.35B to $1.45B -14% YoY At the Midpoint Adjusted EBITDA* $90M to $115M -6% YoY At the Midpoint Operating Cash Flow $60M+ +88% YoY *See "Non-GAAP Financial Measures" section on slide 2 10
Slide 11: Cash Flow Growth in FY27
Cash Flow Growth in FY27 Operating Cash Flow Commentary $MM $60+ • Increasing operational and cost efficiency through technology leverage $32 • PBM stability maintained through multi-year contract • Ramping SelectRx profitability ◦ Driven by the Kansas SelectRx facility $(12) FY25A FY26A FY27E 11
Slide 12: Supplemental Information
Supplemental Information 12
Slide 13: Reconciliation of Non-GAAP Measure
Reconciliation of Non-GAAP Measure Reconciliation of Net Income to Adjusted EBITDA 4Q FY FY YTD (in thousands) 2026 2025 2026 2025 Net income (loss) $ (16,842) $ 12,868 $ 62,189 $ 47,580 Share-based compensation expense 3,382 4,852 14,862 18,357 Transaction costs 634 1,257 2,112 14,617 Depreciation
Slide 14: SelectQuote Inc.
SelectQuote Inc. 6800 West 115th Street Suite 2511 Overland Park, Kansas 66211 Phone: (877) 678-4086 Investor Relations investorrelations@selectquote.com 14